Retatrutide vs Semaglutide (Ozempic / Wegovy): Full Comparison
How the two drugs differ biologically, what clinical trials report about weight reduction, how dosing schedules compare, and which factors may influence tolerability.
Last updated: February 28, 2026
Important: Retatrutide is a research peptide only. Learn more
Key Takeaways
- Semaglutide activates the Glucagon-Like Peptide-1 (GLP-1) receptor only.
- Retatrutide activates GLP-1, Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors.
- Phase 2 data reported 24.2% mean weight reduction at 48 weeks for retatrutide at the highest studied dose.
- Semaglutide (2.4 mg weekly) demonstrated 14.9% mean weight reduction at 68 weeks in the STEP-1 trial.
- Both drugs commonly cause gastrointestinal side effects.
Sources: Jastreboff AM et al., The New England Journal of Medicine, June 26, 2023 | Wilding JPH et al., NEJM, February 10, 2021
What Is the Main Difference Between Retatrutide and Semaglutide?
The main difference lies in receptor activation. Semaglutide activates only the GLP-1 receptor. Retatrutide activates three receptors: GLP-1, GIP, and glucagon. This broader receptor profile increases both appetite suppression and energy expenditure.
Semaglutide primarily reduces caloric intake. Retatrutide reduces intake and increases metabolic output. That dual effect explains the larger weight reductions observed in early retatrutide trials.
How Do They Work?
Semaglutide Mechanism
Semaglutide is a GLP-1 receptor agonist. GLP-1:
- Slows gastric emptying
- Reduces appetite
- Increases insulin secretion after meals
These effects reduce caloric intake, leading to weight loss.
Retatrutide Mechanism
Triple AgonistRetatrutide activates three receptors:
- GLP-1 receptor (appetite reduction)
- GIP receptor (enhances insulin response)
- Glucagon receptor (increases energy expenditure)
The glucagon pathway stimulates fat oxidation and raises metabolic rate. This mechanism adds an energy-burning component absent in semaglutide.
Clinical Trial Results Compared
Retatrutide Data
Phase 2 trial (48 weeks):
Source: NEJM, 2023
Important Context
These results come from separate trials. Direct head-to-head trials have not yet been published. Cross-trial comparisons provide directional insight but do not establish superiority definitively.
Dosing Comparison
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Starting Dose | 2 mg weekly | 0.25 mg weekly |
| Escalation | Every 4 weeks | Every 4 weeks |
| Typical Therapeutic Dose | 8 mg weekly | 2.4 mg weekly |
| Highest Dose | 12 mg weekly | 2.4 mg weekly |
Retatrutide uses higher milligram dosing because it activates three receptors. Milligram comparison alone does not indicate potency.
Side Effects Compared
Shared Side Effects
Both drugs commonly cause:
These effects occur because GLP-1 receptor activation slows gastric emptying.
Retatrutide Differences
- Higher rates of gastrointestinal symptoms at higher doses
- Dose-dependent increases in nausea
- Cardiovascular outcome data not yet published
Semaglutide Differences
- Well-characterised safety profile with multiple large Phase 3 trials
- Cardiovascular outcome data supporting reduced cardiovascular risk in type 2 diabetes populations (SUSTAIN-6 trial)
Source: Marso SP et al., NEJM, 2016
Which Produces Greater Weight Loss?
Phase 2 data suggest retatrutide produces greater average weight reduction than semaglutide. The difference likely results from glucagon receptor activation increasing energy expenditure.
However, semaglutide has more mature Phase 3 data and regulatory approval in multiple jurisdictions. Greater average reduction does not guarantee individual outcomes.
Appetite Suppression vs Energy Expenditure
Semaglutide primarily reduces caloric intake. Retatrutide reduces intake and increases caloric burn. This dual mechanism may explain why some participants in retatrutide trials experienced weight reductions exceeding 20%.
The glucagon receptor activation drives increased lipolysis (fat breakdown), which increases total energy expenditure.
Safety and Regulatory Status
Semaglutide is approved for obesity management under Wegovy and for type 2 diabetes under Ozempic in the UK and US.
Retatrutide remains in clinical development as of February 28, 2026. Approval status influences prescribing availability and insurance coverage.
Practical Considerations
Choose Semaglutide When:
- Regulatory approval is required
- Long-term cardiovascular outcome data are important
- A well-established safety profile is preferred
Consider Retatrutide When:
- Higher weight reduction is the primary goal
- Tolerability at higher doses is acceptable
- Triple agonist mechanism aligns with metabolic targets
Medical supervision is essential for both medications.
Summary Table
| Category | Retatrutide | Semaglutide |
|---|---|---|
| Receptors | GLP-1, GIP, Glucagon | GLP-1 only |
| Mean Weight Loss | Up to 24.2% | ~14.9% |
| Cardiovascular Data | Pending | Established |
| Dose Range | 2-12 mg weekly | 0.25-2.4 mg weekly |
| Regulatory Approval | In development | Approved |
Final Thoughts
Retatrutide demonstrates stronger average weight reduction in Phase 2 trials. Semaglutide offers proven regulatory approval and long-term cardiovascular data. The choice depends on clinical goals, tolerability, and regulatory considerations.
Explore Retatrutide
For dosing details, see our Retatrutide Dosing Guide. For more comparisons, read our Retatrutide vs Tirzepatide article.
Research purposes only